Affinities at the verapamil binding site of MDR1-encoded P-glycoprotein: Drugs and analogs, stereoisomers and metabolites

International Journal of Clinical Pharmacology and Therapeutics

Volumn 38, Issue 4, 2000, Pages 168-179

  Neuhoff, S ^a,b   Langguth, P ^c   Dressler, C ^a   Andersson, T B ^b   Regardh C G ^b   Spahn Langguth, H ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b ASTRAZENECA R AND D   (Sweden)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Binding assay; Enantiomers; Metabolites; P glycoprotein; Structure affinity relationships

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DILEVALOL; GALLOPAMIL; GLYCOPROTEIN P; LABETALOL; OMEPRAZOLE; VERAPAMIL;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; DRUG ABSORPTION; DRUG DISPOSITION; DRUG PROTEIN BINDING; NONHUMAN; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION;

EID: 0034028932     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP38168     Document Type: Article

References (40)

1. Anderle P, Niederer E, Rubas W, Hilgendorf C, Spahn-Langguth H, Wunderli-Allenspach H, Merkle HP, Langguth P 1998 P-glycoprotein-(P-gp) mediated efflux in Caco-2 cell monolayers: the influence of culturing conditions, and drug exposure on P-gp expression levels. J Pharm Sci 87: 757-762
2. Bois F, Beney C, Boumendjel A, Mariotte AM, Conseil G, Di Pietro A 1998 Halogenated chalcones with high-affinity-binding to P-glycoprotein. Potential modulators of multidrug resistance. J Med Chem 41: 4161-4164
3. Conseil G, Baubichon-Cortay H, Dayan G, Jault J-M, Barron D, Di Pietro A 1998 Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein. Proc Natl Acad Sci USA 95: 9831-9836
4. Crevat-Pisano P 1986 Fundamental aspects of radioreceptor assays. J Pharm Biomed Anal 6: 697-716
5. Dayan G, Jault J-M, Baubichon-Cortay H, Baggetto LG, Renoir J-M, Baulieu E-E, Di Pietro A 1997 Binding of steroid modulator to recombinant cytosolic domain from mouse P-glycoprotein in close proximity to the ATP site. Biochem 36: 15208-15215
6. Döppenschmitt S, Spahn-Langguth H, Ragårdh CG, Langguth P 1998 Radioligand-binding assay employing P-glycoprotein-overexpressing cells: testing drug affinities to the secretory intestinal multidrug transporter. Pharm Res 15: 1001-1006
7. Döppenschmitt S, Hanafy A, Langguth P, Spahn-Langguth H 1999a In vivo relevance of competitions at P-glycoprotein: Affinities of vinblastine and rhodamine 123, intestinal permeability and brain distribution. Naunyn Schmiedebergs Arch Pharmacol 359 (Suppl): R119
8. 3H]-verapamil radioligand-binding assay. J Pharmacol Exp Ther 288: 348-357
9. Döppenschmitt S, Spahn-Langguth P, Regårdh CG, Langguth H 1999c The role of P-glycoprotein-mediated secretion in absorptive drug fluxes. J Pharm Sci 88: 1067-1077
10. Gottesman MM 1993 How cancer cells evade chemotherapy: Sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 53: 747-754
11. Hanafy A, Langguth P, Spahn-Langguth H 1998 Tissue distribution of the P-glycoprotein substrate talinolol in rats: influence of verapamil. Naunyn Schmiedebergs Arch Pharmacol 357 (Suppl): R7
12. Hanafy A, Langguth P, Spahn-Langguth H 1999 Interactions between P-glycoprotein substrates: R-talinolol and cyclosporine A-related changes in S-talinolol distribution and intestinal permeability in rats. Arch Pharm 332 (Suppl): 33
13. Haussermann K, Benz B, Gekeler V, Schumacher K, Eichelbaum M 1991 Effects of verapamil enantiomers and major metabolites on the cytotoxicity of vincristine and daunomycine in human lymphoma cell lines. Eur J Clin Pharmacol 40: 53-59
14. Hilgendorf C, Spahn-Langguth H, Langguth P 1997 Intestinal secretion of talinolol: Competitive and P-gp-antibody-induced inhibition of transport in studies with Caco-2 cells. Naunyn Schmiedebergs Arch Pharmacol 355 (Suppl): R127
15. Hilgendorf C 1999 Thesis. The intestinal epithelial barrier in vitro: Carrier-mediated and passive transport in normal and genetically modified Caco-2 cells and other intestinal cell lines. Department of Pharmacy, Martin Luther University Halle-Wittenberg, Halle/ Saale, Germany
16. Horio M, Gottesman MM, Pastan I 1988 ATP-dependent transport of vinblastine in vesicles from human multidrug-resistantcells. Proc Natl Acad Sci USA 85: 3580-3584
17. Hunter J, Hirst BH 1997 Intestinal secretion of drugs: the role of P-glycoprotein and related drug efflux systems in limiting drug absorption. Adv Drug Deliv Rev 25: 129-157
18. Karlsson J, Kuo SM, Ziemniak J, Artursson P 1996 Transport of celiprolol across human intestinal epithelial (Caco-2) cells: mediation of secretion by multiple transporters including P-glycoprotein. Br J Pharmacol 110: 1009-1016
19. Kenakin T 1993 Radioligand-binding experiments. Pharmacological Analysis of Drug-Receptor Interaction. Raven Press, New York, pp 385-411
20. Langguth P, Amidon GL, Lipka E, Spahn-Langguth H 1997 Gastrointestinal transport processes: Potentials for stereoselectivities at substrate-specific and -non-specific epithelial transport systems. Chapter 22. In: Aboul-Enein HY, Wainer IW (eds) The Impact of Stereochemistry on Drug Development and Use. Chemical Analysis Series. John Wiley and Sons, New York, pp 611-632
21. Langguth P, Neuhoff S, Regårdh CG, Spahn-Langguth H 1998 Grapefruit juice components modify the intestinal permeability of the P-glycoprotein substrate talinolol. Exp Toxicol Pathol 50: 117
22. Leville-Webster CR, Arias IM 1995 The biology of the P-glycoproteins. J Membrane Biol 143: 89-102
23. Neuhoff S, Regårdh CG, Spahn-Langguth H, Langguth P 1998 Influence of grapefruit juice components on the intestinal permeability of the P-glycoprotein substrate talinolol. Pharmazie 53: 29
24. Neuhoff S, Norinder U Regårdh CG, Andersson TB, Spahn-Langguth H, Langguth P 1999 Affinity of drugs to the intestinal multidrug carrier P-glycoprotein is predicted using Molsurf parametrization. J Med Chem, manuscript to be submitted; presented at the second AAPS Frontier Symposium: Membrane Transporter and Drug Therapy; NIH, April 8-10, 1999
25. Piquette-Miller M, Foster RT, Kappagoda CT, Jamali F 1992 Pharmacokinetics of acebutolol enantiomers in humans. J Pharm Sci 80: 313-316
26. Romsicki Y, Sharom FJ 1998 The ATPase and ATP-binding functions of P-glycoprotein. Modulation by interaction with defined phosphohpids. Eur J Biochem 256: 170-178
27. Sandström R, Karlsson A, Knutson L, Lennernäs H 1998 Jejunal absorption and metabolism of R/S-verapamil in humans. Pharm Res 15: 856-862
28. Schinkel AH, Smit JJM, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CAAM, van der Valk MA, Rabanus-Maandag EC, te Riele HPJ, Berns AJM, Borst P 1994 Disruption of the mouse mdr1a-P-glycoprotein gene leads to deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77: 491-502
29. Schwarz UI, Gramatté T, Krappweis J, Berndt A, Oertel R, von Richter O, Kirch W 1999 Unexpected effect of verapamil on oral bioavailability of the β-blocker talinolol in humans. Clin Pharmacol Ther 65: 283-290
30. Seelig A 1998 How does P-glycoprotein recognize its substrates? Int J Clin Pharmacol Ther 36: 50-54
31. Soldner A, Christians U, Susanto M, Wacher VJ, Silverman JA, Benet LZ 1999 Grapefruit juice exerts stimulatory effects on P-glycoprotein. Clin Pharmacol Ther 65: 205
32. Spahn H, Wellstein A, Pflugmann G, Mutschler E, Palm D 1989 Radioreceptor assay of metoprolol in human plasma: Comparison with an enantiospecific high-performance liquid chromatographic (HPLC) procedures. Pharm Res 6: 152-155
33. Spahn-Langguth H, Baktir G, Radschuweit A, Okyar A, Terhaag B, Ader P, Hanafy A, Langguth P 1998 P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound. Int J Clin Pharmacol Ther 36: 16-24
34. Spahn-Langguth H, Benet LZ, Möhrke W, Langguth P 1997 First-pass phenomena: sources of stereo-selectivities and variabilities of concentration-time profiles after oral dosage. Chapter 21. In: Aboul-Enein HY, Wainer IW (eds) The Impact of Stereochemistry on Drug Development and Use. Chemical Analysis Series. John Wiley and Sons. New York, pp 573-610
35. Spahn-Langguth H, Langguth P, Schloos J 1996 Evidence for significant contribution of carvedilol metabolites to β-adrenoceptor antagonism: p.o. and i.v. data. Naunyn Schmiedebergs Arch Pharmacol 353 (Suppl): R 158
36. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC 1987 Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84: 7735-7738
37. Wacher VJ, Wu CY, Benet LZ 1995 Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and cancer chemotherapy. Mol Carcinog 13: 129-134
38. Wetterich U, Spahn-Langguth H, Mutschler E, Terhaag B, Rösch W, Langguth P 1996 Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependence of absorption in vitro and in vivo. Pharm Res 13: 514-522
39. Westphal K, Weinbrenner A, Zschiesche M, Franke G, Knoke M, Hachenberg T, Greiner B, Fritz P, Oertel R, Terhaag B, Kroemer HK, Siegmund H 1999 Talinolol - rifampicin interaction: potential role of drug transporters. Naunyn Schmiedebergs Arch Pharmacol 359 (Suppl): R123
40. Zschiesche M, Westphal K, Weinbrenner A, Franke G, Knoke M, Hachenberg T, Terhaag B, Kroemer HK, Siegmund W 1999 Talinolol rifampicin interaction: aspects of stereoselectivity. Naunyn Schmiedebergs Arch Pharmacol 359 (Suppl): R12